Kivo Health

Kivo Health identified a critical gap in chronic obstructive pulmonary disease (COPD) management: patients struggled with fragmented care between pulmonologists, primary care doctors, and emergency departments, leading to preventable hospitalizations and poor symptom control. Rural and underserved patients experienced this most acutely, often traveling hours for specialist appointments while managing daily breathing difficulties without adequate support. The problem was measurable—COPD readmission rates exceeded 20% within 30 days, and patients reported minimal contact with care teams between office visits. Existing alternatives like traditional telehealth and disease management programs offered limited clinical depth, while in-person pulmonology care remained geographically inaccessible for many. Early validation came when Kivo's AI-powered virtual monitoring platform demonstrated it could identify exacerbations before patients required emergency care. Medicare's decision to cover their clinical program signaled strong validation—payers recognized both the clinical efficacy and cost-reduction potential. Patient retention rates above 80% further confirmed that continuous, accessible virtual care addressed a genuine need in this population.

Kivo Health discovered genuine demand when pulmonologists began unprompted referrals of their most difficult chronic obstructive pulmonary disease patients. Rather than relying on surveys asking if doctors wanted AI support, the team tracked actual referral patterns—patients were being enrolled faster than anticipated, with physicians requesting expanded access across their patient populations. The company measured real interest through Medicare claims data, observing that enrolled patients completed their programs at rates exceeding 80%, demonstrating commitment beyond initial signup. Early traction materialized through insurance reimbursement approvals, with payers covering the service based on demonstrated cost reductions and hospital readmission decreases. The strongest validation came from patient behavior: participants showed consistent engagement with daily monitoring and virtual consultations, while their clinical outcomes—measurable improvements in lung function and reduced emergency visits—proved the approach worked in practice. These behavioral signals and measurable health outcomes provided far stronger evidence than any stated interest could offer.